National Center for Advancing Translational Sciences; Notice of Meetings, 49820-49821 [2012-20273]

Download as PDF 49820 Federal Register / Vol. 77, No. 160 / Friday, August 17, 2012 / Notices TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents Activity Number of responses per respondent Total annual responses Average burden per response Total hours Individual In-Depth Interviews .............................. General Public Focus Group Interviews ............... Intercept Interviews: Central Location .................. Intercept Interviews: Telephone ........................... Self-Administered Surveys ................................... Gatekeeper Reviews ............................................ Omnibus Surveys ................................................. 360 144 600 2 10,000 2,400 400 2,400 1 1 1 1 1 1 1 360 144 600 10,000 2,400 400 2,400 0.75 (45 minutes) ......... 1.5 hours ...................... 0.25 (15 minutes) ......... 0.08 (5 minutes) ........... 0.25 (15 minutes) ......... 0.50 (30 minutes) ......... 0.17 (10 minutes) ......... 270 216 150 800 600 200 408 Total (General Public) ................................... Physician Focus Group Interviews ....................... Total (Physician) ............................................ 16,304 144 144 ........................ 1 ........................ ........................ 144 ........................ ....................................... 1.5 hours ...................... ....................................... 2,644 216 216 Total (Overall) ................................................ 16,448 ........................ ........................ ....................................... 2,860 1 There are no capital costs or operating and maintenance costs associated with this collection of information. interviews with callers to test message concepts and strategies following their call-in request to the FDA Center for Tobacco Products 1–800 number. 2 Brief The number of respondents to be included in each new pretest will vary, depending on the nature of the material or message being tested and the target audience. However, for illustrative purposes, table 1 provides examples of the types of studies that may be administered and estimated burden levels that may be incurred during each year of the 3-year period. Time to read, view, or listen to the message being tested is built into the ‘‘Hours per Response’’ figures. Dated: August 13, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–20206 Filed 8–16–12; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health erowe on DSK2VPTVN1PROD with NOTICES National Institute of Dental & Craniofacial Research; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections VerDate Mar<15>2010 17:52 Aug 16, 2012 Jkt 226001 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: September 21, 2012. Open: 8:30 a.m. to 12:00 p.m. Agenda: Report to the Director, NIDCR. Place: National Institutes of Health, Building 31, 31 Center Drive, 6th Floor, 10, Bethesda, MD 20892. Closed: 1:00 p.m. to Adjournment. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, 6th Floor, 10, Bethesda, MD 20892. Contact Person: Alicia J. Dombroski, Ph.D., Director, Division of Extramural Activities, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892. Information is also available on the Institute’s/Center’s home page: https:// www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: August 13, 2012. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–20275 Filed 8–16–12; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Advancing Translational Sciences; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Center for Advancing Translational Sciences Advisory Council. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Cures Acceleration Network Review Board. Date: September 14, 2012. Time: 8:30 a.m. to 2:30 p.m. Agenda: Report from the Acting Institute Director. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Contact Person: Jane A. Steinberg, Ph.D., Executive Secretary, National Center for E:\FR\FM\17AUN1.SGM 17AUN1 Federal Register / Vol. 77, No. 160 / Friday, August 17, 2012 / Notices Advancing Translational Sciences, Bethesda, MD 20892, 301–443–3367. Name of Committee: National Center for Advancing Translational Sciences Advisory Council. Date: September 14, 2012. Open: 8:30 a.m. to 2:30 p.m. Agenda: Report from the Acting Institute Director. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Closed: 3:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Contact Person: Jane A. Steinberg, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, Bethesda, MD 20892, 301–443–3367. Dated: August 13, 2012 Jennifer Spaeth Director, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting erowe on DSK2VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; ZEB1 OSR–D(J1) S T32 Training and R25 Residency and Clinical Fellows Awards Review Meeting. Date: October 11, 2012. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National institutes of Health, DEM II, 6707 Democracy Boulevard, Suite 941, Bethesda, MD 20892. Contact Person: John K. Hayes, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 15:13 Aug 16, 2012 Jkt 226001 Dated: August 9, 2012. Anna P. Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–20272 Filed 8–16–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Office of the Secretary Exercise of Authority Under the Immigration and Nationality Act Office of the Secretary, DHS. Notice of determination. AGENCY: ACTION: Authority: 8 U.S.C. 1182(d)(3)(B)(i). [FR Doc. 2012–20273 Filed 8–16–12; 8:45 am] VerDate Mar<15>2010 Democracy Boulevard, Room 959, Bethesda, MD 20892, 301–451–3398, hayesj@mail.nih.gov. Following consultations with the Secretary of State and the Attorney General, I hereby conclude, as a matter of discretion in accordance with the authority granted to me by section 212(d)(3)(B)(i) of the Immigration and Nationality Act (INA), 8 U.S.C. 1182(d)(3)(B)(i), as amended, as well as the foreign policy and national security interests deemed relevant in these consultations, that paragraphs (iv)(IV), (iv)(V), (iv)(VI), and (i)(VIII) of section 212(a)(3)(B) of the INA, 8 U.S.C. 1182(a)(3)(B), shall not apply with respect to an alien not otherwise covered by the automatic relief provisions of section 691(b) of the Consolidated Appropriations Act, 2008 or by a more specific Exercise of Authority under section 212(d)(3)(B)(i) of the INA, 8 U.S.C. 1182(d)(3)(B)(i), who meets the specifications of paragraphs (a) through (d) of this determination. (a) Alien Qualification: To qualify under this determination, an alien must have: (1) Solicited funds or other things of value for; (2) Solicited any individual for membership in; (3) Provided material support to; or (4) Received military-type training from, or on behalf of, an organization described in paragraph (b). (b) Organization Qualification. An organization meets the specifications of paragraph (a) of this determination if, at any time during the alien’s activities discussed in paragraph (a), it was a terrorist organization as described in subsection 212(a)(3)(B)(vi)(III), 8 U.S.C. 1182(a)(3)(B)(vi)(III), insofar as that organization: (1) Is not identified in either Executive Order 13224, as amended, or PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 49821 otherwise designated by the Secretary of State or the Secretary of the Treasury pursuant to the Specially Designated Nationals List (SDNL), or in lists established by United Nations Security Council Committee pursuant to Resolutions 1267 (1999) or 1988 (2011) concerning Al-Qaida and the Taliban and associated individuals and entities; and (2) Has at no time targeted U.S. interests or persons, including planned or attempted attacks on U.S. interests or persons; engaged in a pattern or practice of torture, as defined in 18 U.S.C. 2441(d)(1)(A), genocide, as described in 18 U.S.C. 1091(a), or the use of child soldiers, as described in 18 U.S.C. 2242; or been designated a terrorist organization as described in subsections 212(a)(3)(B)(vi)(I) or (II) of the INA, 8 U.S.C. 1182(a)(3)(B)(vi)(I) or (II). (c) Additional Qualifications. To meet the requirements of this determination, the alien must also meet the following specifications: (1) On or before the date of this Exercise of Authority, was admitted as a refugee or granted asylum, temporary protected status, or adjustment of status under the Nicaraguan Adjustment and Central American Relief Act (NACARA) or the Haitian Refugee Immigration Fairness Act (HRIFA), or granted a similar immigration benefit other than a non-immigrant visa; or (2) Is the beneficiary of an I–730 Refugee/Asylee Relative Petition filed at any time by such an asylee or refugee. (d) Evidentiary Requirements. An alien must satisfy the relevant agency authority that the alien: (1) Is seeking a benefit or protection under the INA and has been determined to be otherwise eligible for the benefit or protection; (2) Has undergone and passed all relevant background and security checks; (3) Has fully disclosed, to the best of his or her knowledge, in all relevant applications and interviews with U.S. government representatives and agents, the nature and circumstances of each instance of solicitation, material support, and military-type training, and any other activity or association falling within the scope of section 212(a)(3)(B) of the INA, 8 U.S.C. 1182(a)(3)(B); (4) Has not knowingly provided material support to terrorist activities that targeted noncombatant persons, U.S. citizens, or U.S. interests; (5) Has not received training that itself poses a risk to the United States or United States interests (e.g., training on production or use of a weapon of mass destruction, as defined by 18 U.S.C. E:\FR\FM\17AUN1.SGM 17AUN1

Agencies

[Federal Register Volume 77, Number 160 (Friday, August 17, 2012)]
[Notices]
[Pages 49820-49821]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-20273]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of meetings of the 
National Center for Advancing Translational Sciences Advisory Council.
    The meetings will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Cures Acceleration Network Review Board.
    Date: September 14, 2012.
    Time: 8:30 a.m. to 2:30 p.m.
    Agenda: Report from the Acting Institute Director.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, Conference Room 6, Bethesda, MD 20892.
    Contact Person: Jane A. Steinberg, Ph.D., Executive Secretary, 
National Center for

[[Page 49821]]

Advancing Translational Sciences, Bethesda, MD 20892, 301-443-3367.

    Name of Committee: National Center for Advancing Translational 
Sciences Advisory Council.
    Date: September 14, 2012.
    Open: 8:30 a.m. to 2:30 p.m.
    Agenda: Report from the Acting Institute Director.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, Conference Room 6, Bethesda, MD 20892.
    Closed: 3:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, Conference Room 6, Bethesda, MD 20892.
    Contact Person: Jane A. Steinberg, Ph.D., Executive Secretary, 
National Center for Advancing Translational Sciences, Bethesda, MD 
20892, 301-443-3367.

    Dated: August 13, 2012
Jennifer Spaeth
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-20273 Filed 8-16-12; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.